Synthesis and Biological Characterization of 4,4-Difluoro-3-(phenoxymethyl)piperidine Scaffold as Dopamine 4 Receptor (D4R) Antagonist in vitro Tool compounds.

The discovery and characterization of a novel series of 4,4-difluoropiperidine ether-based dopamine D4 receptor antagonists are reported. Structure-activity relationship studies lead to the identification of compound 14a, which displays exceptional binding affinity for the D4 receptor (Ki = 0.3 nm) and remarkable selectivity over other dopamine receptor subtypes (>2000-fold vs. D1, D2, D3, and D5). However, compounds in this series are shown to have poor microsomal stability and high plasma protein binding. Despite these limitations, the exceptional selectivity profile of these compounds makes them valuable tool compounds for investigating the D4 receptor signaling in cellular models of L-DOPA-induced dyskinesias. These findings provide important structural insights into the future development of metabolically stable D4 receptor antagonists for therapeutic applications.